Previous studies have suggested that kidney donors may have abnormalities of mineral and bone metabolism typically seen in chronic kidney disease. This may have important implications for the skeletal health of living kidney donors and for our understanding of the pathogenesis of long-term mineral and bone disorders in chronic kidney disease. In this prospective study, 182 of 203 kidney donors and 173 of 201 paired normal controls had markers of mineral and bone metabolism measured before and at 6 and 36 months after donation (ALTOLD Study). Donors had significantly higher serum concentrations of intact parathyroid hormone (24.6% and 19.5%) and fibroblast growth factor-23 (9.5% and 8.4%) at 6 and 36 months, respectively, as compared to healthy controls, and significantly reduced tubular phosphate reabsorption (-7.0% and -5.0%) and serum phosphate concentrations (-6.4% and -2.3%). Serum 1,25-dihydroxyvitamin D 3 concentrations were significantly lower (-17.1% and -12.6%), while 25-hydroxyvitamin D (21.4% and 19.4%) concentrations were significantly higher in donors compared to controls. Moreover, significantly higher concentrations of the bone resorption markers, carboxyterminal cross-linking telopeptide of bone collagen (30.1% and 13.8%) and aminoterminal cross-linking telopeptide of bone collagen (14.2% and 13.0%), and the bone formation markers, osteocalcin (26.3% and 2.7%) and procollagen type I N-terminal propeptide (24.3% and 8.9%), were observed in donors. Thus, kidney donation alters serum markers of bone metabolism that could reflect impaired bone health. Additional long-term studies that include assessment of skeletal architecture and integrity are warranted in kidney donors.
T
here are compelling reasons to understand the shortand long-term effects of kidney donation on donors. 1, 2 First, it is important to know the adverse consequences of donation to appropriately inform potential donors of inherent risks of donation. Second, kidney donation is an opportunity to better understand the physiological effects of mild reductions in kidney function without the confounding effects of underlying kidney disease.
Whether kidney donors with a glomerular filtration rate less than 60 ml/min per 1.73 m 2 should be classified as having chronic kidney disease as suggested in current guidelines is controversial. 3, 4 One reason to classify someone as having chronic kidney disease is to alert individuals and caregivers to possible preventable or treatable complications. Individuals with chronic kidney disease typically have abnormalities of calcium and phosphorus regulation. 5 Previous studies have reported that kidney donors have increased concentrations of serum parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF23). [6] [7] [8] [9] [10] [11] [12] [13] [14] Studies report that donors have reduced serum concentrations of 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 , calcitriol]. [7] [8] [9] [10] [11] 13 Most studies, however, have been small, with short-term follow-up. Only 1 study has been prospective and controlled, and only 1-year follow-up has been reported. 14 None of these studies has reported a comprehensive assessment of mineral metabolism.
To examine the possible health-related consequences of kidney donation we conducted a prospective, controlled study of living kidney donors and paired normal controls (Assessing Long Term Outcomes in Living Kidney Donors [ALTOLD]). 15, 16 We previously reported that for up to 3 years after donation, serum PTH concentrations were elevated in donors compared to pre-donation values and compared to controls. 16 Because of these observations, and previous reports of elevated PTH and FGF23 concentrations among donors, we measured serum concentrations of intact PTH, intact FGF23, 25-hydroxyvitamin D [25(OH)D], 1,25(OH) 2 D 3 , the tubular reabsorption of calcium and phosphorus, and markers of bone resorption and formation in donors and controls. The results show that 3 years after kidney donation, donors have increased PTH and FGF23 and reduced 1,25(OH) 2 D 3 concentrations, and concomitant increases in serum markers of bone resorption, which if persistent could place donors at risk of increased bone loss in future years.
RESULTS

Participant characteristics
Donors and controls were similar at baseline (Table 1) . Donors were more likely to have a blood relationship to the transplant recipient than were controls. The numbers of participants taking an oral vitamin D, a calcium supplement, or both were similar in controls and donors. There were no differences in body weight or body mass index. The participants differed from living donors in the United States in some important ways: compared to all living donors in the United States, study participants were less likely to be male, more likely to be white, and more likely to be younger. 15 Glomerular filtration rate declined as expected after donation, but increased slightly among donors and declined slightly in controls between visits at 6 and 36 months after donation (Table 2) . Serum albumin concentration appeared to decline slightly over time, but was not different in donors versus controls. C-reactive protein, urine protein, and urine albumin concentrations were similar in donors and controls and changed little before and after donation.
PTH, FGF23, and fractional reabsorption of phosphate At 6 and 36 months serum PTH concentrations had increased in donors compared to controls ( Figure 1 and Table 3 ). Serum FGF23 concentrations were also higher in donors than controls at 6 and 36 months. Increases in serum PTH and FGF23
were associated with a reduction in the tubular reabsorption of phosphate in the donor group, but not in the control group. The serum phosphate concentration was lower in donors than controls at 6 months but not different at 36 months. Serum calcium and fractional tubular resorption of calcium were not affected by kidney donation (Table 3) .
Vitamin D, calcium, and fractional excretion of calcium Serum 1,25(OH) 2 D 3 concentrations were similar in donors and controls before kidney donation, but at 6 and 36 months 1,25(OH) 2 D 3 concentrations were lower in donors compared to controls ( Figure 1 and Table 3 ). Serum 25(OH)D concentrations were similar in donors and controls before kidney donation (Table 3 ). In the donor group, by 6 and 36 months, 25(OH)D concentrations had increased, while 25(OH)D concentrations remained unchanged in controls.
Markers of bone metabolism
We measured markers of bone resorption and bone formation in donors and controls before and at 6 and 36 months after kidney donation. Bone resorption was assessed by measuring serum aminoterminal cross-linking telopeptide of bone type I collagen (NTX), carboxyterminal cross-linking telopeptide of bone type I collagen (CTX), and tartrate-resistant acid phosphatase 5b (TRAP 5b), while bone formation was assessed by measuring osteocalcin (OC), bone alkaline phosphatase (BAP), and procollagen type I N-terminal propeptide (P1NP). Serum NTX and CTX were increased in donors compared to controls at both 6 and 36 months ( Figure 2 and Table 3 ). TRAP 5b concentrations did not change in donors or controls. OC concentrations were higher in donors than controls at 6 and 36 months (Table 3) , while P1NP concentration was higher at 6 months but not different at 36 months (Table 3) . BAP concentrations were higher in donors than controls at 6 and 36 months, but BAP concentrations were also higher in donors than controls at baseline ( Figure 2 and Table 3 ). Altogether the findings are consistent with increased bone turnover in donors compared to controls.
DISCUSSION
The principal findings of the current study at 3 years after kidney donation are that donors show (i) increased serum The current study is the largest prospective study that compares kidney donors to a similar control group not undergoing surgery and selected before donation. We found 9 studies, [6] [7] [8] [9] [10] [11] [12] [13] [14] not including the current study, 15, 16 reporting possible mineral and bone disorders in kidney donors (Supplementary Table S1 online). Of the previous 9 studies, 5 were prospective, comparing changes before and after donation, but did not include normal controls. 6, 7, 10, 12, 13 Three others were retrospective, cross-sectional studies, 8, 9, 11 and 1 of these studies included non-donor controls.
11 Only 1 of the 9 studies was both prospective and controlled.
14 There is considerable heterogeneity in the results of these studies. Some differences may be attributable to study design, particularly with differences in sample size (most being small) and duration of follow-up (most being short). Differences in the results could also reflect differences in assays.
We previously reported that serum phosphate concentration was decreased at 6 and 36 months after donation compared to that in controls. 16 Despite reduced levels of serum phosphate, tubular resorption of phosphate declined ( Table 3 ), indicating that renal phosphate excretion was the likely cause, or at least a contributing factor to the lower serum phosphate concentrations. Although 3 studies reported no change in serum phosphate concentrations, 6 ,10,14 3 others reported a decline in phosphate after kidney donation. 7, 11, 13 All studies that measured tubular resorption of phosphate reported a decline after donation. [6] [7] [8] 10, 11, 13 Both PTH and FGF23 are known to be phosphaturic. [17] [18] [19] Therefore, it is not surprising that both of these hormones were increased in donors compared to controls at 6 and 36 months after donation ( Figure 1 and Table 3 ). Some 7, 11, 13, 14 but not all studies 9,10 also reported that PTH concentrations increased after kidney donation. FGF23 was reportedly increased after kidney donation in 5 studies that measured it. [10] [11] [12] [13] [14] Altogether, these results suggest that for at least 3 years after donation serum PTH and FGF23 are increased, possibly explaining why fractional excretion of phosphate is increased.
The presence of elevated serum FGF23 concentrations despite the presence of hypophosphatemia suggests the presence of autonomous (i.e., not responsive to changes in phosphate concentrations) synthesis of FGF23 in bone osteocytes 20, 21 and supports the notion that bone metabolism is altered in subjects following kidney donation. Elevated PTH concentrations occurring as a result of reduced 1,25(OH) 2 D 3 synthesis and attendant negative calcium balance could serve as the driver of altered bone metabolism and osteocyte activity following kidney donation. It is not known whether alterations in Klotho concentrations contribute to the hypophosphatemia seen following kidney donation. 22 We found that serum 1,25(OH) 2 D 3 was decreased at 6 and 36 months after donation ( Figure 1 and Table 3 ). Similarly, others have reported reduced levels of 1,25(OH) 2 D 3 in kidney donors, 7, [9] [10] [11] 13 while results for 25(OH)D have been equivocal. 7, 11, 13 We found that 25(OH)D 3 and total 25(OH)D were unequivocally increased after donation (Table 3) . These results are consistent with there being inadequate conversion of 25(OH)D 3 to 1,25(OH) 2 D 3 due to the reduction in kidney 
Kidney International (2016) -, ---mass after organ donation, and that this effect persists for at least 3 years after donation. Nevertheless, as previously reported, 7, 8, 10, 11, 13 we found serum calcium to be unchanged after donation, despite the reduced levels of 1,25(OH) 2 D 3 .
There have been few attempts to measure markers of bone metabolism in kidney donors. Ponte et al. measured 2 markers of bone formation (BAP and P1NP) and 1 marker of bone resorption (CTX) in 27 kidney donors before donation, and at 6 months and 1 year after donation. 13 They found that BAP was increased at 6 months but not at 1 year compared to predonation, and P1NP was unchanged at 6 months and 1 year. Bone resorption measured by serum CTX determinations declined at 1 year compared to pre-donation. 13 These results differ from those of the current study. In our study we found definitive evidence for an increase in bone resorption. Indeed, 2 of 3 markers of bone resorption (NTX and CTX) were increased. We also found that 2 markers of bone formation were increased (serum OC and P1NP). These findings suggest that bone turnover may be increased following kidney donation.
It is possible that the differences between donors and controls in mineral bone disorder (MBD) biomarkers seen in the current study simply reflect reduced renal clearance of the molecules and have no long-term consequence to the donors. Indeed, the extent to which increases in biomarkers in donors compared to controls are due to differences in production, nonrenal elimination, or renal elimination is unclear. A very recent study examined single-pass renal clearance of PTH, FGF23, and vitamin D metabolites among 17 individuals from the general population undergoing heart catheterization. 23 The investigators found 44.2% AE 10.3% renal extraction of PTH, which was greater than the extraction of creatinine (22.1% AE 7.9%). The renal extraction of FGF23 was 17.1% AE 19.5%. There were no differences in concentrations of vitamin D metabolites across the renal vein and artery. However, given the much longer plasma half-lives of vitamin D metabolites, the lack of large gradients across the renal artery and vein does not rule out slow renal clearance. We are not aware of other studies that have examined the renal clearance of MBD Table 3 .
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biomarkers in humans. A study in sheep found that plasma clearance of OC was reduced by unilateral nephrectomy. 24 Renal clearance of OC was 50% to 91% of plasma OC clearance, and the authors concluded that the kidney is the major site of OC clearance, although extrarenal sites made a significant contribution. We were unable to find studies directly measuring the renal clearance of the other MBD biomarkers that were examined in the present study. Not knowing the mechanisms for differences in plasma levels of MBD biomarkers between donors and controls does not diminish the potential for these differences to cause or contribute to bone disease. Nevertheless, additional studies into mechanisms causing acute and chronic changes in MBD biomarker concentrations after unilateral nephrectomy would be helpful.
The results of this study should be interpreted with caution. Although many studies have shown that MBD biomarkers correlate with bone mineral content and bone histology, evidence that these biomarkers correlate with fracture risk and outcomes in clinical trials of osteoporosis is weak. 25 Thus, despite the findings in this study, it is not clear whether any of the reported abnormalities in MBD biomarkers cause adverse outcomes of interest to living kidney donors. In a study of 2015 kidney donors in Canada, Garg et al. failed to find an increased number of fractures compared to normal individuals in the general population. 26 Similarly, although PTH, FGF23, and other MBD biomarkers have been found to be independent risk factors for cardiovascular disease in the general population and in patients with CKD, [27] [28] [29] [30] [31] it is unclear whether kidney donation causes an increase in cardiovascular disease events or other adverse outcomes. 32, 33 In summary, the results of this study provide the best evidence to date that mild reductions in kidney function in otherwise normal individuals may cause abnormalities in mineral metabolism. It is unequivocal that kidney donation causes increases in PTH, FGF23, and tubular excretion of phosphate. It is also clear that 1,25(OH) 2 D 3 declines even as Study design and population sample Details of the study design have previously been reported. 15, 16 Consecutive kidney donors at each study site were asked to participate before donation. For donors who consented to participate, a control was found that would have been a suitable donor at the same site as the donor. When more than 1 potential control was available, preference was given to age and sex to match the donor as closely as possible; 182 of 203 (89.7%) original donors and 173 of 201 (86.1%) original controls completed the 36-month follow-up visits. 16 Laboratory measurements Serum and morning urine creatinine, phosphate, and calcium were measured at the University of Minnesota Advanced Research and Diagnostic Laboratory. 15, 16 Table 3 . BCE, bone collagen equivalent.
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